Hand-Foot Syndrome
Recent clinical, regulatory, research and industry developments relating to this disease.
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 industry development reported.
Industry & MarketViewHide
- 2026-09-02Diclofenac Did Not Reduce Chemo-Induced Hand-Foot SyndromeIndustry · Medscape Medical News
- 2026-09-02IndustryDiclofenac Did Not Reduce Chemo-Induced Hand-Foot SyndromeIndustry · Medscape Medical News
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Leading journals1
- The New England journal of medicine1
Leading researchers8
- Aogi K1
- Im SA1
- Im YH1
- Iwata H1
- Jeong J1
- Kim A1
- Kim SB1
- Kuroi K1
Affiliations (unnormalised)1
- From the National Hospital Organization Osaka National Hospital1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Reference
Authoritative identity, definition & identifiers.
Chemotherapy-induced dermal side effects that are associated with the use of various CYTOSTATIC AGENTS. Symptoms range from mild ERYTHEMA and/or PARESTHESIA to severe ulcerative dermatitis with debilitating pain involving typically palmoplantar and intertriginous areas. These cutaneous manifestations are sometimes accompanied by nail anomalies.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.